Find Clinical Trials & Studies

Visit the Research & Education Institute

Pasritamig (JNJ-78278343) in Combination with JNJ-86974680 for Prostate Cancer

I'm Interested!

Please call
1-866-373-1464

A Phase 1b Study of Pasritamig (JNJ-78278343), a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-86974680, an A2a Receptor (A2aR) Antagonist, for Prostate Cancer

Sex: Male
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Prostate

Study Purpose

The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of Pasritamig in combination with JNJ-86974680 in Part 1 (Dose finding) of the study and to determine how safe and tolerable the RP2CD is for treatment of participants with advanced prostate cancer in Part 2 (Dose expansion) of study.

Principal Investigator
Pedro Barata MD

Department/Division
Cancer (Genitourinary)

UH IRB: STUDY20251591
StudyID: JAN3825
ClinicalTrials.gov: NCT07319871

I'm Interested!

Please call
1-866-373-1464

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-866-373-1464